Learning Hub

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Handbook Handbook Understanding Psoriatic Arthritis Handbook Sections What is psoriatic arthritis? What causes psoriatic arthritis? What are the symptoms of psoriatic arthritis? How is psoriatic arthritis diagnosed? Read Sections Living with Psoriatic Arthritis Handbook Sections Work Sleep and fatigue Emotional wellbeing Read Sections Managing Psoriatic Arthritis Handbook Sections How is psoriatic arthritis treated? Non-pharmacological treatments Self-care and lifestyle Read Sections Intimacy, Reproductive Health and Family Life Handbook Sections Relationships and sex Fertility, pregnancy, and breastfeeding Read Sections Psoriatic Arthritis Handbook Handbook

< BACK Europe Day 2024 May 9, 2024 Celebrating Europe Day with iPROLEPSIS sister projects Happy Europe Day 2024! Today we celebrate unity in diversity, innovation and collaboration across the continent. As projects funded under the same Horizon Europe call topic: "Personalised blueprint of chronic inflammation in health-to-disease transition", we're proud to contribute to the common goals of understanding the risk factors that trigger the transition from health to disease, providing personalised prevention measures and reducing the burden of chronic diseases. Within iPROLEPSIS , we aim to develop a suite of digital health tools designed to detect early transitions to psoriatic arthritis, predict flares for timely intervention, and provide personalised recommendations and interventions for managing the disease. With our unique consortium of 15 partners from 9 countries, we are strengthening international and cross-border collaboration to advance research, technology and health progress in Europe and beyond. Join us in commemorating this special day by exploring the impactful work of our sister projects: GlycanTrigger , ENDOTARGET , IMMEDIATE , miGut-Health , AIDA EU project , PREVALUNG EU , PRAESIIDIUM , CARE-IN-HEALTH , Intercept-T2D , INITIALISE , Halt-RONIN , Together, we're shaping a brighter, more inclusive, and sustainable Europe through groundbreaking research and cross-border connections. Europe Day sister projects .png Europe Day sister projects .png 1/1 PREVIOUS NEXT

< BACK The miPROLEPSIS App Now Available for Android Devices on Google Play Store Sep 30, 2024 A data collection tool for the iPROLEPSIS-PDPID study now on Android As of 30 September 2024, the miPROLEPSIS app is available for Android devices on the Google Play Store. The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS - Apps on Google Play 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis treated? Drug treatments See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS at the 2nd Healthy Longevity Symposium Nov 21, 2024 Showcasing the Serious Game Suite for PsA at the Healthy Longevity Symposium The iPROLEPSIS project coordinator, Prof. Leontios Hadjileontiadis , presented the Serious Game Suite for Psoriatic arthritis patients at the 2nd Healthy Longevity Symposium , held by Khalifa University in Abu Dhabi on 21-22 November 2024. The symposium gathered leading experts to explore key topics related to longevity and aging, which is recognised as the root cause of many chronic diseases. The event focused on the latest advancements in aging mechanisms, genomic precision medicine, rejuvenation, and social health policies. Discussions highlighted the potential of AI, advanced technologies, and precision medicine to address the challenges of aging, slow age-related diseases, and improve overall well-being. By integrating cutting-edge research and technology, iPROLEPSIS is advancing innovative solutions aimed at improving the lives of people living with PsA. 1/2 PREVIOUS NEXT

The consortium of iProlepsis project for psoriatic arthritis consists of 15 partners from 9 countries. Discover more about project by visiting our website. About consortium partners iPROLEPSIS project coordinator Aristotle University of Thessaloniki Consortium consists of 15 partners from 9 countries. iPROLEPSIS consortium partners

Clinical experts team Gail Heritage University of Oxford Position Senior Research Manager What is your role in iPROLEPSIS? UK PDPID coordinating center Manager What are your main activities in the project? UK Study manager What is your motivation? Contribution to clinical research to enhance patient experiences and disease outcomes. Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Position Professor What is your role in iPROLEPSIS? Researcher What are your main activities in the project? To try to understand the passage from psoriasis to psoriatic arthritis by evaluating in skin biopsies vascularization, mast cell presence and to correlate this with involved joint vascularization What is your motivation? I would like to discover the connections between skin and joints and find a drug/s that can inhabit this progression Laura Coates Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Position NIHR Research Professor What is your role in iPROLEPSIS? Lead for WP5 (clinical studies) What are your main activities in the project? I oversee all of the clinical studies within the consortium. What is your motivation? I am a rheumatologist who has worked in research in psoriatic arthritis for around 20 years. My interest is in improving outcomes for people living with psoriatic arthritis and I believe that work in this project can help us to predict, monitor and understand the disease better in day to day clinics. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Download iProlepsis project applications for psoriatic arthritis. Apps for download miPROLEPSIS app The miPROLEPSIS app facilitates the iPROLEPSIS-PDPID multicenter clinical study as a data collection tool that will enable the development of digital biomarkers for psoriatic arthritis symptoms and predictive models for inflammation exacerbation. More specifically, the app performs (i) passive data collection from the sensors of the smartwatch used in the study (i.e., Garmin Vivoactive 5), (ii) passive data collection from the accelerometer and gyroscope sensors of the smartphone, (iii) patient reported outcomes via questionnaires. Moreover, the app includes (i) a custom keyboard that captures the user’s typing dynamics and (ii) photo- and video-based activities for the collection of hand/feet photos and skeletal data related to joints flexibility, respectively. Note: The app can be used only by psoriatic arthritis patients that have enrolled to the PDPID study. This enrollment is available for patients in the UK, Netherlands, Portugal, and Greece. Information on how to enroll in the study and gain access to the miPROLEPSIS app will be provided soon. miPROLEPSIS app The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS Joint Landmarker app The miPROLEPSIS Joint Landmarker is an accompanying app of the miPROLEPSIS app that enables the video-based active tests feature. More specifically, a set of 6 hand and body movement exercises are presented and the user is asked to perform them in front of the smartphone camera. The app captures the videos and extracts skeletal data (coordinates of skeletal joints) locally. The skeletal data will be further analysed to develop digital biomarkers that assess the functionality and flexibility of joints. Note: The miPROLEPSIS Joint Landmarker app cannot be used without the miPROLEPSIS app. miPROLEPSIS Joint Landmarker app This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. The videos are immediately discarded and no personal information is retained, saved or transmitted.

< BACK Digital Innovation for Psoriatic Arthritis Prevention Sep 11, 2025 An interview with iPROLEPSIS coordinators in Thessalonikeon Polis on how digital tools, wearables, and AI can help prevent psoriatic arthritis In a recent interview with Thessalonikeon Polis , Vasilis Charisis and Project Coordinator Prof. Leontios Hadjileontiadis from the Signal Processing & Biomedical Technology Unit – AUTH shared insights on the iPROLEPSIS project. The interview highlights the iPROLEPSIS project, showing how smartphones and wearables can assist in early detection and prevention of psoriatic arthritis through digital tools such as wearables, educational games, and personalised apps. It also touches on AI in healthcare, stressing its role in supporting – not replacing – healthcare professionals. Read the full article (in Greek): https://thessalonikeonpolis.gr/machi-kata-tou-parkinson-tehniti-noimosini/ iPROLEPSIS_interview.png iPROLEPSIS_interview.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 7 Jan 28, 2025 Latest News from iPROLEPSIS Welcome to the 7th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_Jan 2025_Issue No. 7 .pdf Download PDF • 5.60MB 1/1 PREVIOUS NEXT

Coordination team Vasilis Charisis Signal Processing & Biomedical Technology Unit (SPBTU) – Aristotle University of Thessaloniki Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Scientific and Technical Coordinator. What are your main activities in the project? I manage the project's day-to-day operations and scientific coherence, driving the timely delivery of outcomes. Our team (SPBTU) is pioneering the use of AI and digital biomarkers from everyday smart devices to create predictive models for PsA symptoms. We are also developing a dedicated mobile app that supports patients by improving sleep patterns using binaural beat technology. What is your motivation? My motivation is rooted in a long-standing commitment to improving chronic disease management through accessible, non-invasive technology. In iPROLEPSIS, I am driven to apply advanced AI and biomedical engineering principles to address the significant challenges faced by PsA patients. We aim to create tangible, personalized digital tools that not only predict disease flares early but actively enhance patients' quality of life, ensuring our cutting-edge research delivers real clinical benefits. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK World Psoriasis Day: iPROLEPSIS featured by HaDEA Oct 29, 2025 On World Psoriasis Day, the European Health and Digital Executive Agency (HaDEA) highlights how the iPROLEPSIS project is advancing early detection and personalised care for psoriatic arthritis Psoriatic arthritis (PsA) is a chronic inflammatory condition that can cause irreversible joint damage if left undiagnosed or untreated. To address this challenge, iPROLEPSIS is developing AI-driven predictive models and digital tools that help identify individuals at risk, enable earlier diagnosis, and support more personalised treatment pathways. In a recent interview with Prof. Leontios Hadjileontiadis , project coordinator, HaDEA explores how iPROLEPSIS brings together clinicians, researchers, and data scientists to transform psoriatic arthritis management across Europe. The discussion covers the project’s use of AI and biological data to build comprehensive patient profiles, its collaborative approach between dermatology and rheumatology, and the importance of EU funding and ethical, cross-border cooperation in enabling innovation. Read the full article on HaDEA’s website: https://hadea.ec.europa.eu/news/world-psoriasis-day-exploration-how-horizon-europe-project-improving-early-detection-psoriatic-2025-10-29_en World Psoriasis Day 2025.png World Psoriasis Day 2025.png 1/1 PREVIOUS NEXT